Tyk2 pseudokinase ligands

A compound having the structure of Formula (I) or Formula (II):

• wherein:
• is C3-C6cycloalkyl, C6-C10aryl, C2-C9heterocycloalkyl, or C2-C9heteroaryl, wherein C3-C6cycloalkyl, C6-C10aryl, C2-C9heterocycloalkyl, or C2-C9heteroaryl is optionally substituted with 1, 2, 3, or 4 R7;
• X is —O—, —C(R9)(R10)—, —C(R9)(R10)—O—, —O—C(R9)(R10), —C(O)—, —C(O)N(R3)—, —N(R3)C(O)—, or —N(R17)—;
• L1 is —C(O)N(R3)—, —N(R3)C(O)—, —C(R9)(R10)—O—, or —O—C(R9)(R10)—;
• L2 is —N(R6)—, —N(R6)CH2—, or —CH2N(R6)—;
• each R1 is independently selected from hydrogen, deuterium, C1-C6alkyl, and C1-C6deuteroalkyl;
• each R2 is independently selected from hydrogen, deuterium, C1-C6alkyl, and C1-C6deuteroalkyl;
• or R1 and R2 are combined to form a 3-, 4-, 5-, or 6-membered cycloalkyl ring or a 4-, 5-, or 6-membered heterocycloalkyl ring;
• each R3 is independently hydrogen or C1-C6alkyl;
• or R2 and R3 together with the atoms to which they are attached are combined to form a 5- or 6-membered heterocycloalkyl ring optionally substituted 1, 2, or 3 with groups selected from halogen, —OH, C1-C6alkyl, and —C1-C6alkyl-OH;
• R4 is selected from hydrogen, deuterium, C1-C6alkyl, C1-C6deuteroalkyl, C1-C6heteroalkyl, C3-C6cycloalkyl, and C2-C9heterocycloalkyl;
• R5 is selected from hydrogen, deuterium, C1-C6alkyl, C1-C6deuteroalkyl, C1-C6heteroalkyl, C3-C6cycloalkyl, and C2-C9heterocycloalkyl;
• R13 is hydrogen, deuterium, C1-C6alkyl, or C1-C6deuteroalkyl;
• or R5 and R13 together with the atoms to which they are attached are combined to form a 5- or 6-membered heterocycloalkyl ring or a 5- or 6-membered heteroaryl ring, wherein the 5- or 6-membered heterocycloalkyl ring or 5- or 6-membered heteroaryl ring is optionally substituted with 1, 2, or 3 groups selected from halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, and C1-C6haloalkoxy;
• R6 is hydrogen or C1-C6alkyl;
• each R7 is independently selected from deuterium, halogen, C1-C6alkyl, C1-C6deuteroalkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6heteroalkyl, oxo, —OR11, —N(R11)2, —CN, —C(═O)R12, —C(═O)OR11, —C(═O)N(R11)2, —NR11C(═O)R12, —NR11S(═O)2R12, —S(═O)2R12, and —S(═O)2N(R11)2;
• each R9 and each R10 are independently selected from hydrogen, deuterium, C1-C6alkyl, and C1-C6deuteroalkyl;
• each R1 is independently selected from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, and phenyl, wherein phenyl is optionally substituted with 1, 2, or 3 groups selected from halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C2-C9heterocycloalkyl, C2-C9heteroaryl, —OR14, —N(R14)2, —C(═O)OR14, and —C(═O)N(R14)2;
• each R12 is independently selected from C1-C6alkyl and C1-C6heteroalkyl;
• each R14 is independently selected from hydrogen, C1-C6alkyl, and C1-C6haloalkyl;
• R17 is hydrogen or C1-C6alkyl;
• R18 is hydrogen, deuterium, halogen, C1-C6alkyl, or C1-C6deuteroalkyl;
• and
• n is 1, 2, 3, or 4;
• or a pharmaceutically acceptable salt or solvate thereof.